NCT01252641View on ClinicalTrials.gov

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

May 31, 2015

Conditions
HIVHIV Infection
Interventions
BIOLOGICAL

SB-728-T

Each infusion will be 5-30 billion modified CD4+ T-cells

Trial Locations (4)

32803

Orlando Immunology Center, Orlando

90035

UCLA CARE Center, Los Angeles

92663

Orange Coast Medical Group, Newport Beach

94115

Quest Clinical Research, San Francisco

Sponsors
All Listed Sponsors
lead

Sangamo Therapeutics

INDUSTRY